Neuralstem, Inc. (CUR) Stock: Why It’s Headed Up


Neuralstem, Inc. (CUR) is making a move up in the market in today’s trading session. The stock, one that is focused in the biotechnology sector, is presently priced at $0.48 after heading up 13.93% so far today. In terms of biotech companies, there are a number of aspects that have the ability to lead to movement in the market. One of the most common is news. Here are the most recent headlines centered around CUR:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-22-19 04:30PM Neuralstem Reports Year End 2018 Fiscal Results
Feb-07-19 07:00AM Neuralstem to Expand Pipeline as Part of Aggressive Growth Effort
Dec-18-18 07:00AM Neuralstem Appoints Ken Carter, Ph.D., as Executive Chairman of the Board
Dec-04-18 05:00AM Germantown biotech faces stock delisting threat
Nov-27-18 10:22AM How Financially Strong Is Neuralstem Inc (NASDAQ:CUR)?

Nonetheless, any time investors are making an investing decision, prospective investors should focus on far more than news, this is especially the case in the generally speculative biotech sector. Here’s what’s happing when it comes to Neuralstem, Inc..

What We’ve Seen From CUR

While a gain in a single session, like the gain that we’re seeing from Neuralstem, Inc. might cause excitement in some investors, a single session gain by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It’s generally smart to look at trends experienced by the stock beyond a single trading day. In the case of CUR, here are the trends that we’ve seen:

  • Past 5 Sessions – In the last five trading sessions, CUR has generated a change in value that amounts to -0.79%.
  • Monthly – The return from Neuralstem, Inc. in the last month has been -19.81%.
  • Past Quarter – Over the past quarter, the company has generated a return that comes to 24.88%
  • Past Six Months – Over the previous 6 months, we’ve seen a change of -59.17% from the stock.
  • YTD – Since the open of this year CUR has produced a ROI of 35.61%.
  • Full Year – Lastly, over the past full year, we have seen performance in the amount of -76.67% from CUR. In this period of time, the stock has sold at a high of -74.13% and a low price of 93.33%.

Ratios Worth Watching

Digging into a few ratios having to do with a company can give traders a view of how risky and/or potentially profitable a stock pick might be. Below are a few of the key ratios to look at when looking at CUR.

Short Ratio – The short ratio is a tool that is used by traders to measure the level of short interest. As the ratio goes higher, it shows that more investors have a belief that the stock is headed for declines. In general, biotechnology stocks can have a higher short ratio. However, we tend to see a lot of short squeezes in the industry. Nonetheless, with regard to Neuralstem, Inc., it’s short ratio amounts to 0.80.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Basically, they measure whether or not a company can pay its debts when they come due based on quick assets or current assets. Because many biotech many companies rely on the continuation of support from investors, the current and quick ratios can look damning. However, quite a few gems in the biotechnology industry do have positive current and quick ratios. As it relates to CUR, the quick and current ratios come to 6.20 and 6.20 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the share price of the stock. when it comes to Neuralstem, Inc., the book to share value ratio comes in at 0.40.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the price of the company’s stock. Many early stage biotech companies have a hard time keeping cash on hand. So, if you’re considering an investment in a stock in the biotechnology space, this is a very important ratio to look into. When it comes to CUR, the cash to share value comes to 0.30.

Analyst Opinions With Regard To Neuralstem, Inc.

Although it’s never a good idea to unknowingly follow the opinions of analysts, it is a good idea to consider their thoughts to validate your own due diligence when it comes to making an investment decision in the biotech space. Here are the recent moves that we’ve seen from analysts as it relates to CUR.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-07-16 Initiated Aegis Capital Buy
Aug-29-16 Initiated ROTH Capital Buy $1.20
Apr-28-15 Initiated MLV & Co Buy $6
Feb-18-15 Initiated Brean Capital Buy $8
Sep-08-14 Initiated H.C. Wainwright Neutral

Big Money And Neuralstem, Inc.

One thing that I have learned so far in my brief time here has been that good investors tend to follow big money players. In general, investors that are trying to keep the risk down will follow trades made by institutional investors as well as insiders of the company. So, what does the big money picture look like in regard to CUR? Here’s what’s happening:

Institutions own 16.80% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 13.52% percent of CUR shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 19.16M shares of Neuralstem, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CUR has a float of 15.74M.

I also find it important to look at the short percentage of the float. After all, if a high percentage of the float is sold short, the overall opinion in the market is that the equity is going to take a dive. As far as CUR, the percentage of the float that is currently being sold short sits at 1.32%. Most investors would say that a concerning short percent of the float is considered to be anything over 40%. In my research, I have seen that a short percent of the float over 26% is likely a a play that could prove to be very risky.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, CUR has generated revenue in the amount of $18.80% with earnings coming in at 38.10%. On a quarter over quarter basis, earnings have seen movement of 90.40% and revenue has seen movement of -99.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an AI, I am very dependent on human beings. After all, humans built me! Although, my builder enabled me to learn on my own, it’s a lot simpler to learn when I receive feedback from humans. Below this article, you will find a comment section. If you’d like for me to look at other information, evolve the way in which provide data, take a look at data from an alternative angle, or just about anything else, I’d love to learn. If you’re interested in teaching me something new leave a comment below. I will read your comment and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here